currently the focus of therapeutic interventions. In this review, we detail recent advances in the annotation of the gene modules and the epigenetic landscape associated with T-cell dysfunction. Together with analysis of single-cell transcriptomes, these findings have enabled a deeper and more precise understanding of the transcriptional mechanisms that induce and maintain the dysfunctional state and highlight the heterogeneity of CD8 + T-cell phenotypes present in chronically inflamed tissue. We discuss the relevance of these findings for understanding the transcriptional and spatial regulation of dysfunctional T cells and for the design of therapeutics.
T-Cell Dysfunction
In chronic disease settings, such as in chronic viral infections and cancer, effector CD8 + T cells progressively acquire an 'exhausted' or dysfunctional T-cell state characterized by variable deficits in their effector functions, including cytotoxicity and the production of proinflammatory cytokines [interleukin-2 (IL-2), tumor necrosis factor-a (TNF-a), interferong (IFN-g)] [1] ( Figure 1A ). Importantly, dysfunctional CD8 + T cells are not completely inert as it has been shown that they can still exert some level of viral control [1] . Moreover, as effector CD8 + T cells lose their ability to produce proinflammatory cytokines, they can acquire the ability to produce IL-10, a potent immune-suppressive cytokine, indicating a potential role for dysfunctional CD8 + T cells in maintaining immune suppression at sites of chronic inflammation. Thus, dysfunctional CD8 + T cells comprise both an obstacle and a liability for successful antiviral and antitumor immunity. Consequently, achieving a deeper understanding of the mechanisms, both CD8 + T-cell extrinsic and intrinsic, which promote the dysfunctional T-cell state, has the potential to inform the development of therapeutic interventions for both chronic viral infections and cancer.
T-cell dysfunction was first recognized in the setting of chronic lymphocytic choriomeningitis virus (LCMV) infection in mice [2, 3] . Studies in this model showed that the repeated triggering of effector CD8 + T cells as a result of antigen persistence was a key factor leading to the progressive loss of effector functions in CD8 + T cells. Later, it was recognized that other CD8 + T-cell extrinsic signals also played important roles in promoting T-cell dysfunction. The loss of CD4 + T cell help, particularly in the form of IL-21 [4] [5] [6] , and signaling downstream of the immunosuppressive cytokines, IL-10 and transforming growth factor-b (TGF-b), were shown to promote T-cell dysfunction [7, 8] . More recently, IL-6 signaling, alone or in combination with TGF-b, was shown to induce the transcription factor Maf, a potential driver of CD8 + T-cell dysfunction in tumor [9] ; however, the role of IL-6 in driving dysfunctional phenotype in vivo was not addressed. That Maf is driven by Stat3 signaling [10] further raises the possibility that other cytokines that activate Stat3 may also play a role in regulating T-cell dysfunction.
Trends
Recent advances have identified novel CD8 + T-cell functional states in chronic inflammatory conditions associated with distinct transcriptional programs.
Single-cell analysis has revealed extensive transcriptional heterogeneity in the CD8 + T-cell response in cancer.
CRISPR/Cas9 genome editing in mature CD8 + T cells has enabled testing of candidate regulators in vivo.
Analysis of the chromatin landscape in CD8 + T cells has revealed distinct epigenetic changes associated with distinct functional states.
Recent advances have provided increased resolution of the cell-intrinsic programs associated with CD8 + T-cell dysfunction. The ability to measure mRNA expression in individual T cells has revealed not only how these distinct transcriptional programs are expressed at the single-cell level but also the heterogeneity present in CD8 + T cells at sites of chronic inflammation.
Although dysfunction has also been described in CD4 + T cells in chronic viral infection [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] (Box 1), in this review we will discuss the recent advances in elucidating the gene modules (see Glossary) and epigenetic landscape associated with CD8 + T-cell dysfunction and discuss a broad framework for understanding the spectrum of CD8 + T-cell phenotypes present in chronically inflamed tissue. 
Molecular Signatures of T-Cell Dysfunction

Gene Modules for T-Cell Dysfunction and Activation
While the dysfunction signatures discussed earlier have been useful in identifying factors that contribute to T-cell dysfunction, it was noted early on that these signatures highly overlap with signatures of healthy T-cell activation (reviewed in [29] ). For example, co-inhibitory receptors (e.g., PD-1, Tim-3, CTLA-4) and effector molecules (e.g., GZMC, IFN-g) present in the dysfunction signatures have been shown to be associated with healthy T-cell activation. This overlap between the dysfunction and activation signatures complicates the identification of molecular mechanisms that drive or maintain dysfunction as opposed to programs that drive T-cell activation and effector differentiation and ultimately give rise to T-cell dysfunction.
Recently, we identified dysregulation of intracellular zinc as having a major role in driving CD8 + T-cell dysfunction [24] . We found that metallothioneins (MT1 and MT2), proteins that function as intracellular zinc chaperones and intracellular zinc availability, are increased in dysfunctional CD8 + TILs [24] . Indeed, loss of MT1 and MT2 expression resulted in normalization of intracellular zinc, improved CD8 + TIL functionality, and tumor growth control in a mouse model of melanoma. Unsupervised analysis of the RNA profiles of TILs from wild-type and MT1/2-deficient mice, in which CD8 + TILs do not exhibit a dysfunctional phenotype, allowed us to obtain a separate ranking of genes by their association with activated and dysfunctional T-cell phenotypes. Using these rankings, we defined four separate modules, consisting of four ranked lists of genes associated with (i) dysfunction (but not activation), (ii) activation (but not and humans [11] [12] [13] [14] [15] [16] . Similar to CD8 + T cells, dysfunctional CD4 + T cells show a loss of the ability to produce cytokines such as IL-2 and TNF-a [13] and acquire the expression of co-inhibitory molecules [12, 14] . Prdm1 (transcription factor also known as BLIMP-1) was reported to drive CD4 + T-cell dysfunction [12] and several other transcription factors such as Eomes and Helios were shown to be upregulated in dysfunctional CD4 + T cells relative to naïve and memory CD4 + T cells [14] . Overall, several transcription factors associated with CD4 + T-cell dysfunction are also implicated in CD8 + Tcell dysfunction, suggesting the evolution of shared regulatory pathways to restrict T-cell responses. Interestingly, viral persistence during chronic LCMV infection has been reported to redirect CD4 + T-cell differentiation toward T follicular The Shared Activation/Dysfunction Module The activation/dysfunction module, defined to be genes that scored highly for both activation and dysfunction, was strongly associated with a previously annotated signature of dysfunctional virus-specific CD8 + T cells in chronic LCMV infection [22] . Included in the activation/ dysfunction module were most co-inhibitory receptors (PD-1, CTLA-4, Tim-3, Lag3, etc.), emphasizing the association of these receptors with states of T-cell activation and dysfunction and underscoring the need for more precise markers to distinguish between activated and dysfunctional CD8 + T-cell states. Interestingly, we found that co-stimulatory receptors (4-1BB, OX-40, GITR) that are members of the TNF superfamily were also included in this gene module, indicating a role for costimulatory receptors belonging to the TNF superfamily in counterbalancing the action of co-inhibitory receptors [24] .
The Dysfunction Module The dysfunction module was defined to be the set of genes that scored highly for dysfunction but lowly for activation, thus specifying a transcriptional program associated with dysfunction that is isolated from CD8 + T-cell activation. That both Gata3 and Helios are zinc finger transcription factors and are high-ranking transcription factors in our dysfunction module is in line with our demonstration that increased zinc availability correlates with the development of dysfunctional phenotype in CD8 + T cells [24] .
Indeed, gene signatures of dysfunctional CD8 + T cells from chronic LCMV infection have also shown enrichment for C2H2-like zinc finger transcription factors [22] , which include Helios. Zinc is an essential metal that is required for the structure and function of over 1000 zinc fingercontaining proteins including not only transcription factors but also serine/threonine kinases, ubiquitin ligases, and matrix metallopeptidases. Thus, one can envision how alterations in zinc availability can have a profound effect on T-cell behavior.
The Activation Module The activation module was defined to be the set of genes that scored highly for activation, but lowly for dysfunction, thus specifying a transcriptional program associated with CD8 + T-cell activation that is isolated from dysfunction. Indeed, highly significant enrichment was observed for this gene module with signatures of naïve CD8 + T cells activated in vitro and weaker but significant enrichments for signatures of CD8 + T cells activated in vivo [24] . Included in this module are genes involved in metabolism (ACAT2), double-strand break repair (RAD50), and mitochondrial ribosome assembly (MTG1).
Heterogeneity of CD8 + T-Cell States within Tumor
The discovery of refined gene modules for T-cell dysfunction, activation/dysfunction, and activation raises the question of how these modules are expressed in individual CD8 + T cells and how this relates to their functional phenotype ( Figure 1B tumor tissue. Intriguingly, among these populations, we found that expression of the activation/ dysfunction module correlates strongly with expression of the activation module, and that while some populations showed diverse expression of numerous modules, others predominantly expressed either the activation and activation/dysfunction or the dysfunction modules. Functional annotation of these novel populations, along with their driving regulators, will greatly advance our understanding of T-cell heterogeneity and function in tumor tissue. Thus, we have discovered a molecular framework that will enable study of the regulation of distinct CD8 + T-cell populations in tumor tissue. Understanding the heterogeneity of CD8 + TILs at such resolution and how the spectrum of CD8 + TILs shifts in response to different perturbations will be highly beneficial for both the evaluation and design of immunotherapies that target the CD8 + T-cell response.
Given the similarity between T-cell dysfunction in the tumor and viral settings, it is of interest to determine whether our gene modules could exist in CD8 + T cells during chronic viral infections. Expanding such single-cell analyses to the chronic viral settings as well as to additional tumor models, and evaluating how the activation, activation/dysfunction, and dysfunction gene modules are expressed in these cells and whether the different CD8 + T-cell populations present in chronic viral infection mirror populations present in cancer will greatly advance our understanding of the dysfunctional phenotype (e.g., by defining precise gene signatures), its heterogeneity across tissues, and its underlying regulatory circuitry.
Regulation of CD8 + T-Cell Dysfunction
Transcription Factors In addition to Gata3 [24] , several other transcription factors have been shown to play a role in promoting CD8 + T-cell dysfunction. The leucine zipper-containing transcription factor Maf was reported to be upregulated in dysfunctional CD8 + TILs in murine melanoma tumors and in TILs from melanoma patients when compared with naïve and effector CD8 + T cells [9] . Loss of Maf resulted in better tumor control while overexpression resulted in dampened TIL accumulation and antitumor activity. Martinez et al. [25] showed that NFAT, which is mostly known for its role in T-cell activation, can promote CD8 + T-cell dysfunction in both tumor and viral infection models when it is not bound to activator protein (AP)-1 transcription factors [25] . Interestingly, Batf, a transcription factor in the AP-1 family, was shown to drive T-cell dysfunction during HIV infection in a pathway downstream of PD-1 [37] . In line with the connection of zinc regulation to T-cell dysfunction, high expression of the zinc finger transcription factor Prdm1 (Blimp-1) has been shown to drive dysfunctional phenotype in chronic LCMV infection [38] .
Some studies have started to delineate how the balance of transcription factor activity impacts on CD8 + T-cell function. Eomesodermin (Eomes) was predicted in a computational analysis to be a key transcription factor involved in CD8 + T-cell dysfunction during chronic LCMV infection In line with the balance of Eomes and T-bet being an important determinant of dysfunctional phenotype, Eomes is associated with the dysfunction module that we have defined, while T-bet is associated with the activation module. In addition, both NFATc1 and Prdm1 are associated with the activation/dysfunction module. Thus, it is possible that other transcription factors in this module (e.g., Bhlhe40 and Hif1a, see Table S4 in [24] ) will have functional roles in determining dysfunctional phenotype.
The identification of transcription factors that drive dysfunctional phenotype and how they are expressed in the settings of chronic viral infection and cancer is essential to understanding how cells enter and maintain the dysfunctional state. In addition, constructing the regulatory networks in which these transcription factors take part will be instrumental for elucidating nodes for intervention. To achieve this, data regarding the gene targets of relevant transcription factors in the setting of T-cell dysfunction must be collected and combinatorial knockout experiments of key regulators will be helpful. Lastly, deeper characterization of the mechanisms by which identified transcription factors are regulated will inform us about cues that push cells to adopt dysfunctional phenotype.
Epigenetics
Beyond transcriptional programs per se, several studies have highlighted the importance of understanding the epigenetic changes associated with CD8 + T-cell dysfunction [43] [44] [45] . These studies showed that the epigenetic landscape of CD8 + T cells significantly varies between the dysfunctional, memory, and effector CD8 + T-cell states [44, 45] . Sen et al. [44] showed that differential regulatory regions in CD8 + T cells between acute and chronic LCMV infections were found mostly away from transcription start sites and gene promoters, and that the dysfunctionspecific epigenetic profiles observed in experimental mouse models are conserved in CD8 state. For example, TLSs have been identified in a number of tumors and their presence is linked to better patient prognosis [46, 47] . Follicular helper T cells are a major constituent of TLSs and were identified as a major cellular source of CXCL13 [48] . Interestingly, CXCR5, the receptor for CXCL13, was found recently to mark a subpopulation of CD8 + T cells that bears a follicular helper T cell-like signature during chronic LCMV infection [18, 20] . A similar population of CXCR5 + CD8 + T cells that inversely correlates with viral load was also identified in HIV patients [18] . While it is unclear whether such a population of CD8 + T cells exists in tumor tissue, the presence of CXCR5 mRNA in tumor tissue has been detected and associated with better breast cancer patient survival [49] . Thus, should a similar population of CD8 + T cells exist in tumor tissue, one might speculate that CXCR5 + CD8 T cells would be recruited to TLSs where they would receive a better T-cell activation signal and thus better sustain functionality.
Implications for Therapy
Immunotherapies, such as co-inhibitory receptor blockade and adoptive T-cell transfer, are transforming the treatment for advanced cancer [50] . Understanding how these therapies work and finding ways to improve them is an active area of research [51] [52] [53] [54] [55] . Technological advances such as in-depth genomic analyses will be instrumental in this regard. Indeed, such analyses have shown that CTLA-4 and PD-1 blockade therapies achieve efficacy through distinct mechanisms [56] . Moreover, transcriptome analyses of responders and nonresponders to PD-1 blockade in cancer patients have begun to elucidate distinct pathways that may be targeted to improve this therapy [57] [58] [59] . Furthermore, the identification of distinct gene modules associated with different functions in CD8 + TIL has laid the groundwork for discovery integrative analysis that combines platforms that assess spatial information such as the immunoscore [60, 61] together with novel computational approaches (e.g., CIBERSORT [62] ) that assess cellular composition in tissue will provide an even more accurate assessment of immune correlation with clinical outcome.
Concluding Remarks and Future Perspectives
Single-cell analysis has the potential to identify new and more refined gene modules in CD8 + T cells. It will be important to discern transient from more stable states, potentially with epigenetic analysis coupled with perturbations (see Outstanding Questions). Testing whether the different transcriptional populations identified by single-cell transcriptomics are distinct in cytotoxicity, cytokine secretion, proliferative capacity, and T-cell receptor expression will resolve their functional relevance. Connecting the transcriptional state of a T cell to its functional role holds great promise to advance our understanding of CD8 + T-cell function and regulation within different systems. Various technologies (e.g., drop-seq, 10X, in-drop, and plate-based technology) currently enable the fast and cost-effective generation of single-cell transcriptomic data at high capture rates. By leveraging these technologies with appropriate computational frameworks and biological validation, it is now possible to transcriptionally characterize in a per-system and percondition manner the T-cell transcriptional landscape across a multitude of environments (e.g., cancer, chronic virus infection) and conditions (e.g., immunotherapy). Thus, connecting the transcriptional heterogeneity observed in T cells with functional phenotype will enable significant advances in our understanding of CD8 + T-cell dysfunction and functional potential. 
